Redhill Consolidated Income from 2010 to 2024

RDHL Stock  USD 0.45  0.03  7.14%   
Check Redhill Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Redhill main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.2 M, Interest Expense of 348.6 K or Selling General Administrative of 18.4 M, as well as many exotic indicators such as Price To Sales Ratio of 1.38, Dividend Yield of 0.0 or PTB Ratio of 4.17. Redhill financial statements analysis is a perfect complement when working with Redhill Biopharma Valuation or Volatility modules.
  
This module can also supplement various Redhill Biopharma Technical models . Check out the analysis of Redhill Biopharma Correlation against competitors.
For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.

About Redhill Biopharma Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Redhill Biopharma income statement, its balance sheet, and the statement of cash flows. Redhill Biopharma investors use historical funamental indicators, such as Redhill Biopharma's Consolidated Income, to determine how well the company is positioned to perform in the future. Although Redhill Biopharma investors may use each financial statement separately, they are all related. The changes in Redhill Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Redhill Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Redhill Biopharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Redhill Biopharma. Please read more on our technical analysis and fundamental analysis pages.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel. Redhill Biophrma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 201 people.

Currently Active Assets on Macroaxis

When determining whether Redhill Biopharma is a strong investment it is important to analyze Redhill Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Redhill Biopharma's future performance. For an informed investment choice regarding Redhill Stock, refer to the following important reports:
Check out the analysis of Redhill Biopharma Correlation against competitors.
For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.
Note that the Redhill Biopharma information on this page should be used as a complementary analysis to other Redhill Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for Redhill Stock analysis

When running Redhill Biopharma's price analysis, check to measure Redhill Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Redhill Biopharma is operating at the current time. Most of Redhill Biopharma's value examination focuses on studying past and present price action to predict the probability of Redhill Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Redhill Biopharma's price. Additionally, you may evaluate how the addition of Redhill Biopharma to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Fundamental Analysis
View fundamental data based on most recent published financial statements
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Is Redhill Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
4
Revenue Per Share
1.008
Quarterly Revenue Growth
(0.96)
Return On Assets
(0.16)
Return On Equity
(8.84)
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.